Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug

Colleen Rivard, Melissa Geller, Erica Schnettler, Manju Saluja, Rachel Isaksson Vogel, Ashok Saluja, Sundaram Ramakrishnan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective Minnelide is a water-soluble pro-drug of triptolide, a natural product. The goal of this study was to evaluate the effectiveness of Minnelide on ovarian cancer growth in vitro and in vivo.

Methods The effect of Minnelide on ovarian cancer cell proliferation was determined by real time electrical impedance measurements. Multiple mouse models with C200 and A2780 epithelial ovarian cancer cell lines were used to assess the efficacy of Minnelide in inhibiting ovarian cancer growth.

Results Minnelide decreased cell viability of both platinum sensitive and resistant epithelial ovarian cancer cells in vitro. Minnelide with carboplatin showed additive effects in vitro. Minnelide monotherapy increased the survival of mice bearing established ovarian tumors. Minnelide, in combination with carboplatin and paclitaxel, improved overall survival of mice.

Conclusions Minnelide is a promising pro-drug for the treatment of ovarian cancer, especially when combined with standard chemotherapy.

Original languageEnglish (US)
Pages (from-to)318-324
Number of pages7
JournalGynecologic Oncology
Volume135
Issue number2
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Prodrugs
Water
Ovarian Neoplasms
Carboplatin
Ovarian epithelial cancer
14-O-phosphonooxymethyltriptolide
Growth
Paclitaxel
Platinum
Biological Products
Electric Impedance
Cell Survival
Cell Proliferation
Drug Therapy
Cell Line

Keywords

  • Chemotherapy
  • Minnelide
  • Ovarian cancer
  • Triptolide

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug. / Rivard, Colleen; Geller, Melissa; Schnettler, Erica; Saluja, Manju; Vogel, Rachel Isaksson; Saluja, Ashok; Ramakrishnan, Sundaram.

In: Gynecologic Oncology, Vol. 135, No. 2, 01.11.2014, p. 318-324.

Research output: Contribution to journalArticle

Rivard, Colleen ; Geller, Melissa ; Schnettler, Erica ; Saluja, Manju ; Vogel, Rachel Isaksson ; Saluja, Ashok ; Ramakrishnan, Sundaram. / Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug. In: Gynecologic Oncology. 2014 ; Vol. 135, No. 2. pp. 318-324.
@article{865db9a0ef754dc184fd34a67507934d,
title = "Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug",
abstract = "Objective Minnelide is a water-soluble pro-drug of triptolide, a natural product. The goal of this study was to evaluate the effectiveness of Minnelide on ovarian cancer growth in vitro and in vivo.Methods The effect of Minnelide on ovarian cancer cell proliferation was determined by real time electrical impedance measurements. Multiple mouse models with C200 and A2780 epithelial ovarian cancer cell lines were used to assess the efficacy of Minnelide in inhibiting ovarian cancer growth.Results Minnelide decreased cell viability of both platinum sensitive and resistant epithelial ovarian cancer cells in vitro. Minnelide with carboplatin showed additive effects in vitro. Minnelide monotherapy increased the survival of mice bearing established ovarian tumors. Minnelide, in combination with carboplatin and paclitaxel, improved overall survival of mice.Conclusions Minnelide is a promising pro-drug for the treatment of ovarian cancer, especially when combined with standard chemotherapy.",
keywords = "Chemotherapy, Minnelide, Ovarian cancer, Triptolide",
author = "Colleen Rivard and Melissa Geller and Erica Schnettler and Manju Saluja and Vogel, {Rachel Isaksson} and Ashok Saluja and Sundaram Ramakrishnan",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.ygyno.2014.08.031",
language = "English (US)",
volume = "135",
pages = "318--324",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug

AU - Rivard, Colleen

AU - Geller, Melissa

AU - Schnettler, Erica

AU - Saluja, Manju

AU - Vogel, Rachel Isaksson

AU - Saluja, Ashok

AU - Ramakrishnan, Sundaram

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Objective Minnelide is a water-soluble pro-drug of triptolide, a natural product. The goal of this study was to evaluate the effectiveness of Minnelide on ovarian cancer growth in vitro and in vivo.Methods The effect of Minnelide on ovarian cancer cell proliferation was determined by real time electrical impedance measurements. Multiple mouse models with C200 and A2780 epithelial ovarian cancer cell lines were used to assess the efficacy of Minnelide in inhibiting ovarian cancer growth.Results Minnelide decreased cell viability of both platinum sensitive and resistant epithelial ovarian cancer cells in vitro. Minnelide with carboplatin showed additive effects in vitro. Minnelide monotherapy increased the survival of mice bearing established ovarian tumors. Minnelide, in combination with carboplatin and paclitaxel, improved overall survival of mice.Conclusions Minnelide is a promising pro-drug for the treatment of ovarian cancer, especially when combined with standard chemotherapy.

AB - Objective Minnelide is a water-soluble pro-drug of triptolide, a natural product. The goal of this study was to evaluate the effectiveness of Minnelide on ovarian cancer growth in vitro and in vivo.Methods The effect of Minnelide on ovarian cancer cell proliferation was determined by real time electrical impedance measurements. Multiple mouse models with C200 and A2780 epithelial ovarian cancer cell lines were used to assess the efficacy of Minnelide in inhibiting ovarian cancer growth.Results Minnelide decreased cell viability of both platinum sensitive and resistant epithelial ovarian cancer cells in vitro. Minnelide with carboplatin showed additive effects in vitro. Minnelide monotherapy increased the survival of mice bearing established ovarian tumors. Minnelide, in combination with carboplatin and paclitaxel, improved overall survival of mice.Conclusions Minnelide is a promising pro-drug for the treatment of ovarian cancer, especially when combined with standard chemotherapy.

KW - Chemotherapy

KW - Minnelide

KW - Ovarian cancer

KW - Triptolide

UR - http://www.scopus.com/inward/record.url?scp=84914115386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914115386&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2014.08.031

DO - 10.1016/j.ygyno.2014.08.031

M3 - Article

C2 - 25172764

AN - SCOPUS:84914115386

VL - 135

SP - 318

EP - 324

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -